First Human Trials Raise Plandai's Profile and Valuation

Marketwired

BALTIMORE, MD--(Marketwired - Jul 23, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, released a research update on Plandai Biotechnology Inc.'s (OTCQB: PLPL). Goldman Small Cap Research believes that by engaging in the upcoming human clinical trials for its flagship product, trials, Plandai has the opportunity to be crowned the Green Tea Extract and bioavailability leader. Furthermore, Goldman notes that the likely favorable results of the trial should enable the Firm to successfully market its product to manufacturers for use in health prevention and wellness, beginning in late 2013.

The Company's upcoming study with KGK will be the first that tests the absorption properties of the Plandai green-tea based Catechin Complex in human subjects. The bioavailability study will not only test the absorption of Phytofare™ Catechin Complex, but it will compare Phytofare™ against a generic green tea extract and a branded product that touts higher bioavailability. In addition, Plandai has also contracted with KGK to simultaneously perform a human weight loss trial to test the effects of Phytofare™ Catechin Complex in inducing weight loss while also improving cholesterol and lowering blood pressure.

In the Goldman Opportunity Research update on the Company, analyst Rob Goldman outlines his investment thesis.

"We believe that the upcoming weight loss trial may be even more important than the traditional trial, given the size of the market for products used in weight loss and the fight against high blood pressure. A number of human clinical trials with green tea extract have been conducted to this end, and while data has been positive, the lack of bioavailability has halted broad use of these products for these applications. In our view, these huge milestone events raise the Company's profile and should substantially increase the Firm's valuation."

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
View Comments (0)